GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (HKSE:09688) » Definitions » Interest Coverage

Zai Lab (HKSE:09688) Interest Coverage : 0 (At Loss) (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Zai Lab Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Zai Lab's Operating Income for the three months ended in Mar. 2025 was HK$-438 Mil. Zai Lab's Interest Expense for the three months ended in Mar. 2025 was HK$-9 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Zai Lab's Interest Coverage or its related term are showing as below:


HKSE:09688's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 116.495
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Zai Lab Interest Coverage Historical Data

The historical data trend for Zai Lab's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Zai Lab Interest Coverage Chart

Zai Lab Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - N/A N/A N/A -

Zai Lab Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Zai Lab's Interest Coverage

For the Biotechnology subindustry, Zai Lab's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zai Lab's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zai Lab's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Zai Lab's Interest Coverage falls into.


;
;

Zai Lab Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Zai Lab's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, Zai Lab's Interest Expense was HK$-18 Mil. Its Operating Income was HK$-2,130 Mil. And its Long-Term Debt & Capital Lease Obligation was HK$107 Mil.

Zai Lab did not have earnings to cover the interest expense.

Zai Lab's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

Here, for the three months ended in Mar. 2025, Zai Lab's Interest Expense was HK$-9 Mil. Its Operating Income was HK$-438 Mil. And its Long-Term Debt & Capital Lease Obligation was HK$96 Mil.

Zai Lab did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Zai Lab  (HKSE:09688) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Zai Lab Interest Coverage Related Terms

Thank you for viewing the detailed overview of Zai Lab's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Zai Lab Business Description

Address
4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
Executives
Fmr Llc 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Du Ying 2101 Beneficial owner
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Wellington Management Group Llp 2102 Investment manager
Janus Henderson Group Plc 2102 Investment manager
Ubs Group Ag 2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd.
Qiming Gp Iv, L.p.
Qiming Venture Partners Iv, L.p.
Qm11 Limited
Invesco Advisers, Inc. 2102 Investment manager
Invesco Developing Markets Fund 2106 Person having a security interest in shares
Baillie Gifford & Co 2102 Investment manager
Citigroup Inc. 2502 Approved lending agent

Zai Lab Headlines

No Headlines